Inactive Instrument

Dishman Carbogen Amcis Ltd Stock price NSE India S.E.

Equities

Pharmaceuticals

End-of-day quote NSE India S.E.
- INR 0.00% Intraday chart for Dishman Carbogen Amcis Ltd
Sales 2022 21.41B 258M Sales 2023 24.13B 291M Capitalization 19.56B 236M
Net income 2022 180M 2.17M Net income 2023 -298M -3.59M EV / Sales 2022 2.02 x
Net Debt 2022 14.27B 172M Net Debt 2023 19B 229M EV / Sales 2023 1.6 x
P/E ratio 2022
161 x
P/E ratio 2023
-65.6 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 29.93%
More Fundamentals * Assessed data
Dishman Carbogen Gets 'Few Procedural Observations' after US FDA Inspection of Bavla Unit MT
Transcript : Dishman Carbogen Amcis Limited, Q3 2024 Earnings Call, Feb 15, 2024
Dishman Carbogen Amcis Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Transcript : Dishman Carbogen Amcis Limited, Q2 2024 Earnings Call, Nov 09, 2023
Dishman Carbogen Amcis Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Transcript : Dishman Carbogen Amcis Limited - Shareholder/Analyst Call
Transcript : Dishman Carbogen Amcis Limited, Q1 2024 Earnings Call, Aug 10, 2023
Dishman Carbogen Amcis Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
INDIA STOCKS-Indian shares subdued as US debt ceiling deadlock fuels caution RE
Transcript : Dishman Carbogen Amcis Limited, Q4 2023 Earnings Call, May 23, 2023
Dishman Carbogen Amcis Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Dishman Carbogen Amcis Plans to Issue Debentures MT
Transcript : Dishman Carbogen Amcis Limited, Q3 2023 Earnings Call, Feb 10, 2023
Dishman Carbogen Amcis Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Dishman Carbogen Amcis Unit Opens New Sterile Liquid Drug Facility in France MT
More news
Managers TitleAgeSince
Chief Executive Officer 38 12-04-06
Director of Finance/CFO 42 -
Chief Operating Officer - -
Members of the board TitleAgeSince
Chairman 73 07-03-16
Director/Board Member 73 17-03-16
Director/Board Member 76 17-03-16
More insiders
Dishman Carbogen Amcis Limited is engaged in contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules, such as specialty chemicals, vitamins and chemicals, and disinfectants. The Company's segments include CRAMS and Vitamin - D, Bulk Drugs, Quats, Specialty Chemicals and traded goods. The Company assists pharma companies through various stages of drug development from process research and development to late-stage clinical and commercial manufacturing facilities, along with the supply of active pharmaceutical ingredients (APIs) and intermediates. The Company has manufacturing and research facilities in India, Switzerland, France, Netherlands, United Kingdom and China. The Company's subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd., CARBOGEN AMCIS Holding AG and Dishman Biotech Ltd.
More about the company
  1. Stock
  2. Equities
  3. Stock Dishman Carbogen Amcis Limited
  4. Stock Dishman Carbogen Amcis Ltd - NSE India S.E.